SCHEMBL16035364

SCHEMBL16035364

N#Cc1cn(Cc2cccc(F)c2)c2nc(Br)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ XDH P47989 1/20 0.42
▸ TSHR P16473 1/20 0.40
▸ ADORA2A P29274 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ DPP4 P27487 1/20 0.38
▸ PKM P14618 2/20 0.37
▸ PRNP P04156 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CYP11B1 P15538 1/20 0.37
▸ CYP11B2 P19099 1/20 0.37
▸ DBH P09172 1/20 0.36
▸ MKNK1 Q9BUB5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16035573 0.79 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2TDP1MEN1KMT2A
SCHEMBL16035304 0.75 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2TDP1MEN1KMT2A
SCHEMBL16035284 0.74 STAT6 (0.45) ALDH1A1SMN1; SMN2DPP4CYP11B1CYP11B2
SCHEMBL29483670 0.71 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2TDP1MEN1KMT2A
SCHEMBL28597325 0.71 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2TDP1MEN1KMT2A
SCHEMBL21268792 0.68 HRH3 (0.38) ALDH1A1MEN1KMT2AKDM4EHSD17B10
SCHEMBL22128367 0.68 SMN1; SMN2 (0.36) SMN1; SMN2XDH
SCHEMBL29483663 0.68 TP53 (0.53) ALDH1A1SMN1; SMN2TDP1MEN1KMT2A
SCHEMBL28606088 0.68 TP53 (0.53) ALDH1A1SMN1; SMN2TDP1MEN1KMT2A
SCHEMBL29630606 0.67 ELANE (0.58) ALDH1A1SMN1; SMN2TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970268-A1 CDK9 KINASE INHIBITORS AbbVie Inc. (US) 2016-01-20 — — EP disclosed
US-8969375-B2 CDK9 kinase inhibitors ABBVIE, INC. (US) 2015-03-03 — — US disclosed
WO-2014159999-A1 CDK9 KINASE INHIBITORS ABBVIE INC. (US) 2014-10-02 — — WO disclosed
US-20140275153-A1 CDK9 KINASE INHIBITORS ABBIVE INC. 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275153-A1 CDK9 KINASE INHIBITORS CDK9, CDK19, CDK10 ALDH1A1 3063/4885SMN1; SMN2 2026/4885TDP1 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback